Darunavir: meta-analysis of COVID-19 studies

All studies Mortality Serious outcomes Viral clearance RCTs Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (5)−34%

Mortality (4)−34%

Viral clearance (1)−22%

RCTs (1)−22%

Early (1)−22%

Late (4)−34%

00.511.5+

← Darunavir
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Darunavir COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Chen (RCT)−22%1.22 · 0.53–2.78viral+15 (n)15 (n)

Early treatment−22%1.22 · 0.55–2.7215 (n)15 (n)22% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.64

Nicolini−32%1.32 · 0.85–2.06death151 (n)177 (n) Kim87%0.13 · 0.02–0.68death2/1414/28 Milic−150%2.50 · 1.58–3.94death115 (n)158 (n) Di Castelnuovo−89%1.89 · 1.53–2.34death479 (n)1,824 (n)CORIST

Late treatment−34%1.34 · 0.76–2.382/75914/2,18734% higher risk

Tau² = 0.25, I² = 84.1%, p = 0.32

All studies−34%1.34 · 0.82–2.202/77414/2,20234% higher risk

Tau² = 0.22, I² = 79.7%, p = 0.2400.511.52+

Rotate screen for more detailsIncrease width for more details

← Darunavir
reduces riskDarunavir
increases risk →

c19early.org

October 2026

Darunavir COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Nicolini−32%1.32 · 0.85–2.06151 (n)177 (n) Kim87%0.13 · 0.02–0.682/1414/28 Milic−150%2.50 · 1.58–3.94115 (n)158 (n) Di Castelnuovo−89%1.89 · 1.53–2.34479 (n)1,824 (n)CORIST

Late treatment−34%1.34 · 0.76–2.382/75914/2,18734% higher risk

Tau² = 0.25, I² = 84.1%, p = 0.32

All studies−34%1.34 · 0.76–2.382/75914/2,18734% higher risk

Tau² = 0.25, I² = 84.1%, p = 0.3200.511.52+

Rotate screen for more detailsIncrease width for more details

← Darunavir
reduces riskDarunavir
increases risk →

c19early.org

October 2026

Darunavir COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Late treatment−34%1.34 · 0.76–2.382/75914/2,18734% higher risk

Tau² = 0.25, I² = 84.1%, p = 0.32

All studies−34%1.34 · 0.76–2.382/75914/2,18734% higher risk

Tau² = 0.25, I² = 84.1%, p = 0.3200.511.52+

Rotate screen for more detailsIncrease width for more details

← Darunavir
reduces riskDarunavir
increases risk →

c19early.org

October 2026

Darunavir COVID-19 viral clearance results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Chen (RCT)−22%1.22 · 0.53–2.78viral+15 (n)15 (n)

Early treatment−22%1.22 · 0.55–2.7215 (n)15 (n)22% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.64

All studies−22%1.22 · 0.55–2.7215 (n)15 (n)22% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6400.511.52+

Rotate screen for more detailsIncrease width for more details

← Darunavir
reduces riskDarunavir
increases risk →

c19early.org

October 2026

Darunavir COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Chen (RCT)−22%1.22 · 0.53–2.78viral+15 (n)15 (n)

Early treatment−22%1.22 · 0.55–2.7215 (n)15 (n)22% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.64

All studies−22%1.22 · 0.55–2.7215 (n)15 (n)22% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6400.511.52+

Rotate screen for more detailsIncrease width for more details

← Darunavir
reduces riskDarunavir
increases risk →

c19early.org

October 2026

Darunavir COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Chen (RCT)−22%1.22 · 0.53–2.78viral+15 (n)15 (n)

Early treatment−22%1.22 · 0.55–2.7215 (n)15 (n)22% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.64

Late treatment−34%1.34 · 0.76–2.382/75914/2,18734% higher risk

Tau² = 0.25, I² = 84.1%, p = 0.32

All studies−34%1.34 · 0.82–2.202/77414/2,20234% higher risk

Tau² = 0.22, I² = 79.7%, p = 0.2400.511.52+

Rotate screen for more detailsIncrease width for more details

← Darunavir
reduces riskDarunavir
increases risk →

c19early.org

October 2026

Darunavir COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Chen (RCT)−22%1.22 · 0.53–2.78viral+15 (n)15 (n) Nicolini−32%1.32 · 0.85–2.06death151 (n)177 (n) Kim87%0.13 · 0.02–0.68death2/1414/28 Milic−150%2.50 · 1.58–3.94death115 (n)158 (n) Milic−48%1.48 · 1.04–2.11death/int.115 (n)158 (n) Di Castelnuovo−89%1.89 · 1.53–2.34death479 (n)1,824 (n)CORIST

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Darunavir
reduces riskDarunavir
increases risk →